RxDoctor Payments DataLook up a doctor →

Christopher Vulin, MD

Urology · Saint Louis, MONPI 1801870126

Payments from drug & device makers

$8,479in general payments, 2019–2025

Across 364 payments — averaging $23.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$1K
  • Pfizer$644
  • Sumitomo Pharma America, Inc.$604
  • Dendreon Pharmaceuticals LLC$600
  • Accord Healthcare, Inc.$510
  • Ferring Pharmaceuticals Inc.$492
  • plus $5K from 35 others

What the payments were for

  • Consulting fees$1001%
  • Food & beverage$8,23597%
  • Education$941%
  • Gifts$501%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,479 in reported general payments places this provider in the 75th percentile of 250 urology providers in Missouri.

See all urology providers in Missouri

Medicare billing

Part B allowed, 2024
$397,352
Medicare patients
795
Services billed
13,282

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide178$2,517,344
NubeqaDarolutamide18$247,600
MyrbetriqMirabegron166$100,526
GemtesaVibegron94$71,061
OrgovyxRelugolix24$63,986
Tamsulosin Hcl1,083$14,263
Finasteride1,213$11,241
Mirabegron ErMirabegron12$8,509
Dutasteride316$7,588
Solifenacin Succinate153$5,740
Silodosin13$3,519
Potassium Citrate ErPotassium Citrate18$2,480
Alfuzosin Hcl ErAlfuzosin Hcl122$2,090
Testosterone Cypionate64$1,611
Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl21$1,571

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$1,016$2,617,871344 claims
BayerNubeqa$404$247,60018 claims
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$604$135,047118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 250 urology providers in Missouri.

Other urology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →